The patient with hybrid CTCs shown in Figure 3H (#13) was a 52-year-old woman, which was diagnosed with Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) of NST, stage cT2N3M0, HR+, HER2-negative, four years prior to donating the CTC sample. This evidence concerns the gene ERBB2 and invasive lobular breast carcinoma.